Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$4.07 USD
+0.28 (7.39%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.06 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Absci Corporation [ABSI]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
ABS-101 Update Positive; Additional Partnerships by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
ABS-101 Validates AI Platform and Attracts Partnership Interest; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Advancing Internal Pipeline and Expecting to Gain Additional Partnered Programs in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Key Takeways From Our AI-Based Drug Discovery and Development Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
ABS-101 Development Update; Higher $7 PT Reflects New Partnerships; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Announces New Strategic RD Partnership with PrecisionLife to Target Up to Five Chronic Disease Targets
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Digital Biology Tech- Enabled Drug Discovery Initiation
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
New Partnership Generates Two Active Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
A Multi-Asset Pipeline of AI-Created Biologics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Another Active Program Added; Expect to Ramp up in Coming Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Progress Continues in Generating Partnerships and Active Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Absci Corporation
Industry: Medical - Biomedical and Genetics
Spearheading AI-Based Protein Drug Discovery With Unrivaled Synthetic Biology Capability; Initiate With Buy and a $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|